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INTRODUCTION
Allogeneic bone marrow transplantation (BMT) offers a
potential cure for chronic myelogenous leukemia (CML),
albeit at the price of transplant-related mortality and morbid-
ity. Allogeneic BMT across ABO-mismatch barriers carries
additional risks for these patients, including hemolysis and
delayed red blood cell (RBC) engraftment. In particular,
major ABO blood group–mismatched graft recipients may
show signs of hemolysis at the time of transplant due to lysis
of RBCs in the graft or at the time of erythroid engraftment
due to reticulocytosis in the presence of persistent anti-ABO
antibodies, or of prolonged RBC transfusion dependence due
to delayed or absent eythroid engraftment [1–5]. 
Immediate hemolysis at the time of BMT may be avoid-
ed by RBC depletion of the graft before infusion or by low-
ering the recipient anti-ABO titer in vivo before BMT by
plasmapheresis or immunadsorption [1–8]. Hemolysis at the
time of engraftment is usually not clinically signiﬁcant, but
in rare severe cases may be treated with plasmapheresis [9].
Delayed erythroid engraftment is well documented and usu-
ally responds to supportive care or erythropoietin therapy
[9–12]. Rare cases of erythroid aplasia refractory to these
measures have been reported; however, no consensus exists
as to optimal management [8,13–17]. Nevertheless, major
ABO-mismatched BMT has not generally been associated
with poor patient survival [1–4].
Recently we reported that in our institution, patients
with acute myelogenous leukemia (AML) or myelodysplastic
syndrome (MDS) who received an ABO-mismatched BMT
were signiﬁcantly more likely to die of regimen-related toxi-
city than recipients of ABO-identical grafts [18]. This
increased risk was not apparent in a larger group of similarly
treated CML patients. In our AML and MDS patients,
major ABO-mismatch transplantation was associated with a
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Erythroid engraftment after non–T cell–depleted allogeneic bone marrow transplant (BMT) is reviewed in 112
patients treated for chronic myelogenous leukemia (CML). Twenty-two of 76 evaluable patients were transplanted
over a major ABO-mismatch compatibility barrier. These patients showed an increased delay in erythroid engraft-
ment and in time to red blood cell transfusion independence when compared with ABO-identical or minor mis-
matched recipients. No difference in granulocyte or platelet engraftment was evident. Erythroid engraftment usual-
ly occurred spontaneously without specific intervention. One patient was found to have erythroid hypoplasia at day
201 after BMT, despite therapy with intravenous immunoglobulin and high-dose erythropoietin. An anti-A titer of
16,000 was documented. This patient was successfully treated with an aggressive course of 18 plasmapheresis pro-
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significant delay in erythroid engraftment. Given the dis-
crepancy in early survival rates, we asked whether major
ABO-mismatch affected the rate of hematopoietic recovery
in our CML patient group.
MATERIALS AND METHODS
Patients
One hundred twelve patients undergoing HLA-matched
or single-antigen–mismatched, non–T cell–depleted allo-
geneic BMT at the Brigham and Women’s Hospital between
January 1993 and June 1997 were studied retrospectively, as
previously described [18]. Surviving patients were followed
for a median of 537 days (range 120–1512 days). The patient
characteristics are shown in Table 1. All protocols were
approved by the Brigham and Women’s Hospital Institution-
al Review Board, and both recipients and donors gave writ-
ten informed consent.
Patients were divided into four groups based on donor-
recipient ABO compatibility: ABO-identical (group I); ABO
major-mismatched (e.g., group A grafts given to group O
recipients; group II); major plus minor ABO-mismatched
(e.g., group A grafts given to group B recipients; group III);
and minor ABO-mismatched (e.g., group O grafts given to
group A recipients; group IV). Group I and IV stem cell
products were infused without manipulation, while group II
and III grafts were infused after RBC depletion as described
[19]. Our transfusion policy dictated that all transplant
recipients receive leuko-depleted irradiated blood products
and single-donor apheresis platelets. RBC and plasma com-
ponents were restricted to an ABO type compatible with
both donor and recipient RBCs (e.g., group A donor receiv-
ing  group B bone marrow [BM] would be restricted to
group O RBCs and group AB plasma). ABO-compatible
platelets were given preferentially, if available, but no rou-
tine policy was in place to remove incompatible plasma from
either platelet or RBC components. 
Conditioning regimen and graft-vs.-host disease prophylaxis
The conditioning regimen and supportive care were
described previously [18,20,21]. Graft-vs.-host disease (GVHD)
prophylaxis comprised cyclosporine (CSA) and methotrexate
(MTX) with or without added steroids [22].
Outcomes
Evaluable patients were those who survived at least 100
days after BMT. Endpoints included: granulocyte engraft-
ment, defined as the first day after transplant that
200106/L granulocytes was attained for at least 3 days;
RBC transfusion dependence, deﬁned as the number of days
from transplant until the ﬁrst RBC transfusion that was fol-
lowed by at least 30 days without RBC transfusion; and
RBC engraftment, defined as the number of days from
transplant until a reticulocyte count of 0.5% was attained.
Reticulocyte counts were performed once a week until
engraftment and complete data were available for 64 (84%)
of 76 patients who survived at least 100 days after transplant.
Case history
Universal patient number (UPN) 1449 is a 44-year-old
Caucasian male who presented for transplant with a 21-month
history of stable-phase, Philadelphia chromosome-positive
CML. His disease was well controlled on hydroxyurea and
interferon therapy. He underwent an HLA-matched, unrelat-
ed donor, non–T cell–depleted BMT following cytoxan and
total-body irradiation (Cy/TBI) conditioning. At the time of
transplant, he had no signiﬁcant family, surgical, or medical
history and had not received prior transfusions. Clinical exam-
ination was unremarkable. Laboratory investigations showed
that he was blood group O, Rh-positive and conﬁrmed CMV-
negative status. Immunoglobulin (Ig) G anti-A titer was meas-
ured at 256 at the antihuman globulin phase using standard
techniques [23]. He received a blood group A, Rh-negative,
CMV-negative, RBC-depleted BM graft, and GVHD prophy-
laxis consisted of CSA, MTX, and Pred. The early posttrans-
plant course was marked by moderate mucositis, mild veno-
occlusive disease, and a single episode of coagulase-negative
Staphylococcus bacteremia, which responded to vancomycin.
Granulocyte engraftment (200106/L) occurred on day 30
and platelet counts 20,000/mL were maintained without
transfusion by day 40. At discharge from the hospital, the
patient had grade II GVHD, which was evidenced by a ﬁne
maculo-papular rash that was responsive to increased steroid
therapy. GVHD prophylaxis consisted of CSA 450 mg b.i.d.
and Pred 200 mg q.d., which was gradually tapered over the
ensuing months. He remained RBC transfusion-dependent,
requiring approximately two units of group O, Rh-negative,
packed RBCs every two weeks. Erythropoietin levels taken at
day 96 were elevated at 109 U/mL (normal 0–27 U/mL) and
haptoglobin levels were within normal range. At that time,
white blood cell count (WBC) was 2570/L, platelet count
was 25,000/L, and reticulocytes were 0.1%. There were no
signs of GVHD and CMV cultures, and Parvovirus serology
were negative. He was given 32 g intravenous (i.v.) Ig on day
Table 1. Patient characteristics
Number of patients
ABO- Major ABO- Minor ABO-
Total compatible mismatcha mismatch
Ageb 40 (22–60) 40 42 40
Gender
Men 64 33 19 12
Women 48 22 16 10
Total 112 55 35 22
Donor
Related 60 35 13 12
Matched unrelated 52 20 22 10
Conditioning
Cy/TBI 98 49 32 17
AraC/Cy/TBI 14 6 3 5
GVHD prophylaxis
MTX/CSA 60 36 14 10
FK506/MTX 8 2 4 2
MTX/CSA/Pred 43 16 17 10
Syngeneic 1 1 0 0
aIncludes six major plus minor ABO-mismatched graft recipients.
bMedian and (range).
ABO, ABO blood group; AraC, cytosine arabinoside; CSA, cyclosporine A; Cy,
cytoxan; FK506, tacrolimus; GVHD, graft-vs.-host disease; MTX,
methotrexate; Pred, prednisone; TBI, total-body irradiation.
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118 to enhance erythroid engraftment. By day 131, his WBC
fell to 1000/L and platelets were 16,000/L. The possibili-
ties of viral-induced marrow suppression or late graft failure
were entertained. At this time, GVHD prophylaxis included
CSA 200 mg b.i.d. and prednisone 5 mg q.d. The patient was
started on acyclovir and granulocyte-macrophage colony-
stimulating factor (GM-CSF), and BM biopsy revealed a
hypocellular marrow with 10% cellularity, consisting predom-
inantly of myeloid precursors. No erythroid or megakaryocyt-
ic elements were seen. By day 152, his WBC had risen to
10,400/mL and the GM-CSF was stopped. Platelet count
remained at 24,000/mL, hematocrit at 28.5, and reticulocytes
at 0.6%. Given the lack of appropriate reticulocytosis, ery-
thropoeitin was started on day 173 at 4000 U 3 times a week.
On day 188, this was increased to 10,000 U 3 times a week. A
peak reticulocyte count of 0.8% was obtained and the patient
remained transfusion-dependent. An anti-A IgG titer per-
formed on day 201 post-BMT was 16,000, and a diagnosis of
refractory antibody-mediated RBC hypoplasia was made. At
this time, the direct antiglobulin test (DAT) was negative and
haptoglobin and direct and indirect bilirubin levels were with-
in normal range. A polymerase chain reaction test for the
BCR/ABL oncogene product was negative, confirming his
CML remission status.
Statistical analysis
All statistics were performed using SPSS for Windows,
Release 6.1 (SPSS, Chicago, IL). Univariate analyses of
patient survival were performed using Kaplan-Meier sur-
vival analysis [24]. Comparison of the distributions of bino-
mial variables between patients receiving ABO-identical and
-incompatible transplants were performed using the SPSS
Exact Test (based on Fischer’s exact test). For all analyses, p
 0.05. 
RESULTS
Erythroid engraftment after ABO-mismatched BMT
We reviewed all patients receiving an allogeneic BMT
for CML. One hundred ten stable-phase and two accelerat-
ed-phase CML patients received allogeneic non–T
cell–depleted grafts from related (60 patients) or unrelated
(52 patients) donors (Table 1). Most patients received
Cy/TBI (98 patients) conditioning followed by MTX/CSA
(60 patients) or MTX/CSA/Pred (43 patients) GVHD pro-
phylaxis. We analyzed the effect of graft ABO-mismatch on
survival and hematopoietic recovery in this population.
Thirty-six (32%) of 112 patients died within 100 days of
BMT. There was no significant difference in survival rate
between ABO-identical and -incompatible graft recipients
[18]. The surviving 76 patients were considered evaluable
for this study. These included 40 ABO-identical, 16 major
ABO-, 14 minor ABO-, and 6 major plus minor ABO-mis-
matched graft recipients. 
Hematopoietic recovery and transfusion requirements
were examined. Overall, in the evaluable patients, granulo-
cytes and reticulocytes recovered on median day 21 and 22,
respectively, and a median of 10 units of RBCs and 8 units
of single-donor apheresis platelets were transfused in the
ﬁrst 100 days after transplant. There was no signiﬁcant dif-
ference in granulocyte engraftment or platelet transfusion
requirements between the ABO-identical and -incompatible
groups (major plus minor ABO-mismatched patients were
grouped with the major ABO-mismatched graft recipients
for these analyses). 
In contrast, major ABO-mismatched recipients received
significantly more RBC transfusions, took significantly
longer to engraft RBCs, and remained RBC transfusion-
dependent longer than ABO-identical recipients (Figure 1).
Indeed, median time to RBC engraftment was delayed from
21 to 32 days ( p  0.003) and median duration of RBC
transfusion independence from 26 to 47 days (p  0.001) in
major mismatched compared with ABO-identical recipients
(Table 2). Major ABO-mismatched recipients also required
an average of six more RBC transfusions (p  0.03) than did
the other groups.
We conclude that major ABO-mismatched recipients
showed delayed erythroid engraftment, without an effect on
granulocyte or platelet engraftment. Note that our BMT
protocol did not routinely assess anti-ABO titers and no
Figure 1. Cumulative proportion of patients remaining erythroid aplastic (A) or RBC transfusion dependent (B) after allogeneic BMT
In each case, major ABO-mismatched ( ) recipients are signiﬁcantly different from ABO-identical ( ) (p  0.003) and minor ABO-mismatched 
( ) (p  0.05) recipients. 
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attempt was made to reduce anti-ABO titers either before or
after BMT. Nevertheless, 21 of 22 major ABO-mismatch
recipients showed spontaneous erythroid engraftment with-
out the need for speciﬁc therapy. The one notable exception
was UPN 1449, who was found to have anti-A antibody
mediated RBC hypoplasia on day 201 after unrelated BMT
(anti-A titer 16,000) despite high-dose erythropoietin and
i.v. gammaglobulin therapy (see “Case history” above).
Successful treatment of refractory erythroid aplasia
without additional immunosuppression
Because most previously described strategies for enhanc-
ing RBC engraftment in the setting of major ABO-mis-
matched BMT advocate the use of immunosuppressive
modalities, we elected to pursue a novel approach: UPN
1449 received an aggressive course of therapeutic plasma
exchange (TPE) with donor-type plasma replacement. Eight
single-volume plasma exchanges were performed over 2
weeks on the Cobe Spectra cell separator (Cobe, Lakewood,
CO), followed by 10 similar procedures over the following 6
weeks. This therapy was well tolerated and no unusual aller-
gic reactions were noted. After ﬁve procedures, the IgG anti-
A titer dropped to 256 (Fig. 2), and after 12 procedures, to 8.
Thereafter, the patient noted an increase in appetite, his
platelet counts increased to within normal range, and reticu-
locyte counts rose progressively to a maximum of 7.2%.
These changes were accompanied by the development of a
positive DAT, an RBC eluate notable for anti-A1 antibodies,
and a progressive blood group switch on forward typing to
donor blood group A. Lactate dehydrogenase and total and
indirect bilirubin levels remained within normal range. The
patient required his last RBC transfusion on day 271, 2
Table 2. Transfusion and engraftment parameters of all patients surviving 100 days
Graft ABO match All patients ABO compatible Major mismatch Minor mismatch
(Number of patients) (76) (40) (22) (14)
Number of platelet transfusions in first 100 days 8 (0–81)a 7 (1–81) 9 (0–67) 7 (2–71)
Number of RBC transfusions (units) 10 (0–58) 8 (0–58) 14 (4–41)b 9 (2–38)
RBC transfusion dependence (days) 29 (0–273) 26 (0–144) 47 (16–273)c 25 (7–157)
RBC engraftment (days) 22 (13–152) 21 (13–70) 32 (14–152)c 21 (17–50)
Granulocyte engraftment (days) 21 (13–35) 20 (13–34) 23 (13–35) 19 (17–25)
Statistical signiﬁcance determined relative to ABO-compatible recipients.
aAll data are shown as median and (range).
bp  0.03 (Student’s t-test).
cp  0.003 (Kaplan-Meier statistics).
Figure 2. UPN 1449 
Anti-A titers () and percentage reticulocytes () during the course of therapeutic plasma exchange with donor-type plasma replacement. , timing of plasma
exchange procedures.
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months after initiating TPE therapy. Over the subsequent 6
months, he demonstrated a rising hematocrit with no clinical
evidence of hemolysis and the DAT became negative.
DISCUSSION
Major ABO-mismatched BMT has previously been asso-
ciated with acute hemolysis at the time of transplant and with
delayed erythroid engraftment in patients transplanted for a
variety of diseases. Acute hemolysis may be avoided by
reduction of the recipient anti-ABO titer in vivo, by TPE or
donor-type RBC transfusion, or by simply removing the
RBC from the graft before infusion [1–8]. Delayed erythroid
engraftment is associated with the use of CSA for GVHD
prophylaxis and is independent of the recipients’ pretrans-
plant anti-ABO titer [5,8]. Major ABO-mismatched BMT
does not affect the rate of granulocyte or platelet engraft-
ment and prior reports have shown no effect on patient sur-
vival [1–4]. Recently, we have shown that in our institution,
patients receiving both major and minor ABO-mismatched,
non–T cell–depleted BMT for AML or MDS were at signiﬁ-
cantly increased risk of death within the first 100 days of
transplant [18]. This was not the case for 112 CML patients.
In that study, AML or MDS patients who received major
ABO-mismatched grafts showed delayed erythroid engraft-
ment and prolonged RBC transfusion dependence. Given
the difference in the overall effect on survival, we asked
whether major ABO-mismatch had any effect on erythroid
engraftment in the same cohort of CML patients.
We now report that in 22 of 76 CML patients who
received related or unrelated non–T cell–depleted, major
ABO-mismatched BMT and who survived at least 100 days
posttransplant, erythroid engraftment and RBC transfu-
sion independence was delayed to a median of 32 and 47
days, respectively. The major ABO-mismatched recipients
also required six more RBC transfusions than ABO-identi-
cal recipients. No significant effect on granulocyte engraft-
ment or platelet transfusion requirements was apparent.
The overall effect of major ABO-mismatch on erythroid
recovery in CML patients was similar to that previously
reported in our AML and MDS patient group [18]. These
data suggest that delayed hematopoeitic recovery is not
responsible for the previously documented differences in
early mortality rates.
In most of our CML patients, the erythroid engraftment
occurred spontaneously and did not require speciﬁc therapy
other than RBC transfusion support. In ﬁve patients, pro-
longed transfusion dependence led to the measurement of
peripheral blood erythropoietin levels, which were raised in
all but one patient who manifested inappropriately low ery-
thropoietin synthesis that was secondary to renal insufﬁcien-
cy (data not shown). 
We describe in detail one patient who developed pro-
longed erythroid hypoplasia that was refractory to i.v. Ig and
erythropoietin therapy, with raised endogenous erythropoi-
etin levels and an IgG anti-A titer of 16,000 assessed on day
201 posttransplant. This patient responded to an aggressive
course of 18 TPE procedures with donor-type plasma
replacement. This led to erythroid engraftment, RBC trans-
fusion independence, and an increased feeling of well-being
and appetite, with no signs of ongoing hemolysis.
We were unable to examine risk factors for prolonged ery-
throid hypoplasia because of the retrospective nature of this
study. It is, however, noteworthy that UPN 1449 had a rela-
tively high pre-BMT anti-A titer of 256 and received CSA
prophylaxis for GVHD. These factors have previously been
implicated in delayed erythroid engraftment [8].
Prolonged erythroid aplasia following major-mismatched
BMT is thought to be due to persistently raised isohemagglu-
tinin titers that suppress erythropoiesis. BM biopsies reveal
an absence of erythroid precursors, while in vitro culture
reveals exuberant blast forming unit-erythroid (BFU-E)
colony formation [25–27]. These data support the notion that
ABO antigens are increasingly expressed after the BFU-E
developmental stage and that these cells are speciﬁcally lysed
by anti-A or -B isohemagglutinins. In most major ABO-
mismatched patients, the incompatible anti-A or -B titer
decreases spontaneously after transplant and reticulocytosis
occurs when the IgG titer falls to 8–16 [5,8]. This is often
accompanied by a transiently positive DAT with signs of
extravascular hemolysis. The process of engraftment in these
cases can be accelerated by the use of erythropoietin therapy
or by single TPE procedures with donor-type plasma
replacement [9–12,28,29]. Prolonged erythroid aplasia that
persists for 6 months and is refractory to erythropoietin
therapy is a rare occurrence, and the published experience
consists of a collection of case reports [8,15,17,26]. There is,
therefore, no consensus as to optimum therapy. Various
modalities have proven ineffective, including the use of i.v. Ig,
steroids, and plasmapheresis with albumin solution replace-
ment. Successful therapies have included exchange transfu-
sion with donor-type RBCs or immunosuppressive modali-
ties, such as antithymocyte globulin or the combination of
erythropoietin and bolus methylprednisone [12–17,30]. We
reasoned that the risks of exchange transfusion were unac-
ceptable and that further immunosuppressive therapy was
undesirable in our patient [31]. We therefore attempted a
novel protocol consisting of aggressive plasma exchange with
donor-type plasma. This approach was based on the rationale
that plasma from donors who are secretors (80% of the
population) contains A or B substance capable of neutralizing
anti-A or -B isohemagglutinins. Previous studies showed that
plasma is equivalent in neutralizing power to a 1% solution of
RBCs [4]. A one-to-one mixture of secretor plasma and
group O (containing both anti-A and -B antibodies) plasma
results in a 16- to 64-fold decrease in anti-A titer or a zero- to
eightfold decrease in anti-B titer [32]. Donor-type plasma has
also been shown to be effective in reducing anti-A or -B titers
when used in plasma exchange before allogeneic BMT and to
decrease anti-A or -B titers after BMT by simple infusion
[4,33]. We have not proven that the use of donor-type plasma
was necessary for the success of our approach; however, the
step-wise decrease in anti-A titer after each plasma exchange
and the poor results previously reported with conventional
TPE argue in favor of its efficacy. The use of donor-type
plasma may interfere with the determination of patient iso-
hemagglutinin titers. For this reason, we continued TPE
therapy in our patient until we documented an erythroid
ABO type switch rather than a fall in isohemagglutinin titers
to 8, as has previously been suggested [5,8].
Finally, we have shown that delayed erythroid engraft-
ment is not uncommon after major ABO-mismatched BMT
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for CML; however, this does not routinely require speciﬁc
intervention such as erythropoietin therapy. Conversely,
refractory erythroid aplasia is rare and may be responsive to
plasma exchange with donor-type plasma, without a require-
ment for additional immunosuppressive modalities.
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